BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines. In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...includes targets mentioned in at least 10 of the 268 abstracts ASCO designated with a “TPS”...
...targets were then mapped to the 16 indications that were mentioned in at least 25 TPS...
BioCentury | May 19, 2017
Clinical News

Incyte reports Phase I/II data for epacadostat plus Keytruda ahead of ASCO

...of stable disease, in 7 patients whose tumors expressed PD-1 with a tumor proportion score (TPS...
...received ≤2 prior lines of therapy. In 17 patients whose tumors expressed PD-1 with a TPS...
BioCentury | Dec 21, 2016
Clinical News

Keytruda regulatory update

...lung cancer (NSCLC) in adults whose tumors express PD-L1 with a ≥50% tumor proportion score (TPS...
...of locally advanced or metastatic NSCLC in adults whose tumors express PD-L1 with a ≥1% TPS...
BioCentury | Dec 16, 2016
Company News

Celltrion biosimilar among CHMP recommendations

...EGFR and ALK mutation-negative patients whose tumors express PD-L1 with a ≥50% tumor proportion score (TPS...
BioCentury | Oct 27, 2015
Clinical News

Merck's Keytruda improves OS in NSCLC study

...primary endpoints of the trial, which enrolled 1,034 patients with PD-L1 expression tumor proportion scores (TPS...
...with significantly longer OS in the intent-to-treat population, as well as in a subgroup with TPS...
...Merck said both doses significantly improved progression-free survival (PFS) vs. docetaxel in the subgroup with TPS...
BioCentury | Jan 31, 2000
Company News

Bioanalytical, T.P.S. Inc. deal

BASI, which sells instrument systems for the biochemistry and physiology markets, acquired T.P.S., a provider of preclinical toxicology, pathology and chemistry services. Bioanalytical Systems Inc. (BASI), West Lafayette, Ind. T.P.S. Inc. , Evansville, Ind. Business: Supply/Service...
BioCentury | Apr 15, 1996
Clinical News

Lifecore regulatory update

...mm diameter products in the Sustain HA-Coated Threaded Dental Implant product line and the Restore TPS-Coated...
BioCentury | Feb 5, 1996
Company News

Escagenetics agbio, cancer news

...ESN and its subsidiaries - TPS Products Co. and PHYTOpharmaceuticals Inc. - filed for Chapter 11...
Items per page:
1 - 10 of 18